Applied Dna Sciences Inc (NASDAQ: APDN) |
|
Price: $0.1689
$0.00
-0.822%
|
Day's High:
| $0.1719
| Week Perf:
| -0.76 %
|
Day's Low: |
$ 0.17 |
30 Day Perf: |
-25.92 % |
Volume (M): |
1,081 |
52 Wk High: |
$ 14.40 |
Volume (M$): |
$ 183 |
52 Wk Avg: |
$2.62 |
Open: |
$0.17 |
52 Wk Low: |
$0.12 |
|
|
Market Capitalization (Millions $) |
1 |
Shares
Outstanding (Millions) |
4 |
Employees |
50 |
Revenues (TTM) (Millions $) |
3 |
Net Income (TTM) (Millions $) |
-7 |
Cash Flow (TTM) (Millions $) |
-1 |
Capital Exp. (TTM) (Millions $) |
0 |
Applied Dna Sciences Inc
Applied DNA Sciences Inc is a biotechnology company that specializes in utilizing DNA-based technologies to address unique challenges in various industries. They offer a range of services including DNA tagging, authentication, and tracking of products to prevent counterfeiting and fraud. The company's main focus is on industries such as textiles, pharmaceuticals, and supply chain, where their DNA-based solutions have the potential to revolutionize how products are verified and protected. Applied DNA Sciences Inc strives to provide innovative and secure solutions that give businesses and consumers peace of mind in the authenticity of their products.
Company Address: 50 Health Sciences Drive Stony Brook 11790 NY
Company Phone Number: 240-8800 Stock Exchange / Ticker: NASDAQ APDN
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Applied Dna Sciences Inc
Applied DNA Sciences Inc, a leading provider of DNA-based security solutions, recently released its second quarter financial report for 2024, painting a less than ideal picture for the company. The report revealed a disappointing -78.909% decline in revenue, which dropped to a mere $0.93 million. Moreover, the shortfall per share also expanded to a staggering $-5.31, compared to the same reporting period the previous year. In a slight silver lining, the revenue did witness a sequential increase of 4.316% from the preceding reporting period, starting at $0.89 million. However, this minor growth did not make up for the overall loss in revenue experienced by the company.
|
Applied Dna Sciences Inc
The financial results of Applied Dna Sciences Inc for the first quarter of 2024 paint a mixed picture, with both positive and negative aspects to consider. Facts: - Loss per share decreased from $-0.30 to $-0.09 compared to a year ago, indicating an improvement in the company's bottom line. - Earnings per share also showed improvement, increasing from $-0.21 in the previous reporting period. - Revenue saw a significant decrease of -83.067% to $0.89 million from $5.26 million in the comparable reporting period a year prior. However, revenue surged by 50.091% sequentially from $0.59 million. - Applied Dna Sciences Inc reported a net shortfall of $-1.130 million in the first quarter of 2024, a significant improvement from the deficit of $-3.844 million in the same period a year ago. - Stockpiles increased to $0.4 million, though still below the previous year's level of $0.5 million. - The value of accounts receivable is lower than the previous year, but there has been some sequential progress. Context: - Applied Dna Sciences Inc shares have seen a 6.25% drop in the last five trading days, contributing to a year-to-date performance of -7.4%. - Shares are currently trading only 10.6% above their 52-week low, suggesting that the company may be facing some challenges in the market.
|
Applied Dna Sciences Inc
Applied DNA Sciences Inc, a company specializing in Electronic Instruments & Controls, recently disclosed its financial performance for the period ending September 30, 2023. The results showcased significant declines in revenue and a widening net deficit per share compared to the previous year. These developments, coupled with a decline in stock prices and a decrease in stockpiles, indicate challenging times ahead for the company. Declining Financial Results: During the past five days, Applied DNA Sciences Inc stock experienced a substantial decline of 26.14%. Furthermore, the stock's value dropped by 23.45% compared to the previous year. It is currently trading on NASDAQ, 12% below its 52-week average. These figures paint a grim picture for the company's immediate prospects.
|
Applied Dna Sciences Inc
Applied DNA Sciences Inc. is a company that specializes in providing molecular-based security and authentication solutions to various industries. They utilize unique DNA markers to ensure the integrity and traceability of products, with applications ranging from supply chain security to anti-counterfeiting measures. However, the latest financial report for the company may raise some concerns for investors. From April to June 30, 2023, Applied DNA Sciences Inc. experienced a significant increase in their loss per share, with it reaching $-0.24 per share compared to $-0.13 per share in the previous year. Additionally, their income per share fell from $0.05 per share in the prior reporting period.
|
Applied Dna Sciences Inc
Applied Dna Sciences Inc (APDN) has seen a significant turnaround in its financial performance in the period ending March 31, 2023. Despite a decline in revenue of 28.3% to $4.41 million, APDN managed to post positive earnings per share of $0.05 compared to a loss of $0.23 per share a year prior. The EPS turned positive from $-0.30 per share in the preceding quarter, indicating a clear upward trend in performance. APDN's net profits of $0.551 million in the financial period ending March 31, 2023, is a vast improvement from the net deficit of $-1.760 million in the same quarter a year ago. These results suggest that the company's management has made significant strides in restructuring and improving its financial operations.
|
Per Share |
Current |
Earnings (TTM) |
-6.88 $ |
Revenues (TTM) |
0.76 $
|
Cash Flow (TTM) |
- |
Cash |
1.62 $
|
Book Value |
2.26 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-6.88 $
|
Revenues (TTM) |
0.76 $ |
Cash Flow (TTM) |
- |
Cash |
1.62 $
|
Book Value |
2.26 $ |
Dividend (TTM) |
0 $ |
|
|
|
Research and development services (over-time) |
|
7.51 % |
of total Revenue |
Clinical laboratory testing services (point-in-time) |
|
1.65 % |
of total Revenue |
Clinical laboratory testing services (over-time) |
|
39.07 % |
of total Revenue |
Supply chain |
|
24.33 % |
of total Revenue |
Large Scale DNA Production |
|
27.44 % |
of total Revenue |
Product revenues |
|
30.93 % |
of total Revenue |
Service revenues |
|
28.36 % |
of total Revenue |
Clinical laboratory service revenues |
|
40.72 % |
of total Revenue |
Therapeutic DNA Production |
|
34.95 % |
of total Revenue |
MDx Testing Services |
|
40.72 % |
of total Revenue |
DNA Tagging and Security Products |
|
24.33 % |
of total Revenue |
Operating segment Product revenues |
|
30.93 % |
of total Revenue |
Operating segment Service revenues |
|
28.36 % |
of total Revenue |
Operating segment Therapeutic DNA Production Product revenues |
|
27.44 % |
of total Revenue |
Operating segment Therapeutic DNA Production Service revenues |
|
7.51 % |
of total Revenue |
Operating segment MDx Testing Services Clinical laboratory service revenues |
|
40.87 % |
of total Revenue |
Operating segment DNA Tagging and Security Products Product revenues |
|
3.48 % |
of total Revenue |
Operating segment DNA Tagging and Security Products Service revenues |
|
20.85 % |
of total Revenue |
Less intersegment revenues MDx Testing Services |
|
-0.15 % |
of total Revenue |
Product revenues |
|
30.93 % |
of total Revenue |
Service revenues |
|
28.36 % |
of total Revenue |
Therapeutic DNA Production Product revenues |
|
27.44 % |
of total Revenue |
Therapeutic DNA Production Service revenues |
|
7.51 % |
of total Revenue |
MDx Testing Services Clinical laboratory service revenues |
|
40.87 % |
of total Revenue |
DNA Tagging and Security Products Product revenues |
|
3.48 % |
of total Revenue |
DNA Tagging and Security Products Service revenues |
|
20.85 % |
of total Revenue |
Less interrevenues MDx Testing Services |
|
-0.15 % |
of total Revenue |
|
|